Akari Therapeutics, Plc Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)
Akari Therapeutics, Plc (AKTX) reported Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) of -$99.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2026-08-13
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2026-06-30 was -$99.00K, a 173.88% decline year-over-year.
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2026-03-31 was $44.00K.
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2025-12-31 was $442.00K, a 71.61% decline year-over-year.
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2025-09-30 was $253.00K, a 743.33% increase year-over-year.
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2025 was $775.00K, a 62.83% decline from fiscal 2024.
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2024 was $2.08M, a 68.40% decline from fiscal 2023.
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2023 was $6.60M, a 5.00% decline from fiscal 2022.
- Akari Therapeutics, Plc fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2022 was $6.95M.
| Period end | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month as first filed | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month as first filed | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$99.00K 10-Q · filed 2026-08-13 | -$55.00K 10-Q · filed 2026-08-13 | $387.00K derived: sum of 3 quarters · filed 2026-08-13 | $640.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $44.00K 10-Q · filed 2026-05-19 | $486.00K derived: sum of 2 quarters · filed 2026-05-19 | $739.00K derived: sum of 3 quarters · filed 2026-05-19 | $873.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $695.00K derived: sum of 2 quarters · filed 2026-03-30 | $829.00K derived: sum of 3 quarters · filed 2026-08-13 | $775.00K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $253.00K 10-Q · filed 2025-11-13 | $387.00K derived: sum of 2 quarters · filed 2026-08-13 | $333.00K 10-Q · filed 2025-11-13 | $1.89M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $134.00K 10-Q · filed 2026-08-13 | $80.00K 10-Q · filed 2026-08-13 | $1.64M derived: sum of 3 quarters · filed 2026-08-13 | $1.67M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$54.00K 10-Q · filed 2026-05-19 | $1.50M derived: sum of 2 quarters · filed 2026-05-19 | $1.53M derived: sum of 3 quarters · filed 2026-05-19 | $1.38M derived: sum of 4 quarters · filed 2026-05-19 | |||
| 2024-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.59M derived: sum of 2 quarters · filed 2026-03-30 | $1.44M derived: sum of 3 quarters · filed 2026-03-30 | $2.08M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $30.00K 10-Q · filed 2025-11-13 | -$121.00K derived: sum of 2 quarters · filed 2025-11-13 | $528.00K 10-Q · filed 2025-11-13 | $1.24M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$151.00K 10-Q · filed 2025-08-13 | $498.00K 10-Q · filed 2025-08-13 | $1.21M derived: sum of 3 quarters · filed 2025-08-13 | $950.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $649.00K 10-Q · filed 2025-05-14 | $1.36M derived: sum of 2 quarters · filed 2025-05-14 | $1.10M derived: sum of 3 quarters · filed 2025-05-14 | $1.66M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $710.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $452.00K derived: sum of 2 quarters · filed 2025-04-15 | $1.01M derived: sum of 3 quarters · filed 2025-04-15 | $6.60M 10-K · filed 2025-04-15 | |||
| 2023-09-30 | -$258.00K 10-Q · filed 2024-11-19 | $302.00K derived: sum of 2 quarters · filed 2024-11-19 | $5.89M 10-Q · filed 2024-11-19 | ||||
| 2023-06-30 | $560.00K 10-Q · filed 2024-08-19 | $6.15M 10-Q · filed 2024-08-19 | $6.15M 6-K · filed 2023-09-29 | ||||
| 2023-03-31 | $5.59M 10-Q · filed 2024-05-15 | ||||||
| 2022-12-31 | $6.95M 10-K · filed 2024-03-29 | ||||||
| 2021-12-31 | $0.00 20-F · filed 2023-05-01 | ||||||
| 2020-12-31 | $159.44K derived: 20-F 12 month − 20-F 9 month · filed 2023-05-01 | $1.16M derived: sum of 2 quarters · filed 2023-05-01 | -$392.65K derived: sum of 3 quarters · filed 2023-05-01 | $556.81K 20-F · filed 2023-05-01 | |||
| 2020-09-30 | $1.00M 20-F · filed 2021-04-21 | -$552.09K derived: sum of 2 quarters · filed 2021-09-22 | $397.37K 20-F · filed 2021-04-21 | $397.37K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-06-30 | -$1.56M 6-K · filed 2021-09-22 | -$2.43M 6-K · filed 2020-09-01 | -$606.15K 6-K · filed 2021-09-22 | -$1.12M 6-K · filed 2020-09-01 | -$606.15K derived: sum of 3 quarters · filed 2022-05-16 | -$407.20K derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-03-31 | $949.46K 20-F · filed 2021-04-21 | $949.46K derived: sum of 2 quarters · filed 2022-05-16 | $1.15M derived: sum of 3 quarters · filed 2022-05-16 | $2.98M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2019-12-31 | $0.00 derived: 20-F 12 month − 20-F 9 month · filed 2022-05-16 | $198.95K derived: sum of 2 quarters · filed 2022-05-16 | $2.03M derived: sum of 3 quarters · filed 2022-05-16 | $198.95K 20-F · filed 2022-05-16 | -$60.64K 20-F · filed 2020-03-31 | ||
| 2019-09-30 | $198.95K 20-F · filed 2021-04-21 | $2.03M derived: sum of 2 quarters · filed 2021-04-21 | $198.95K 20-F · filed 2021-04-21 | ||||
| 2019-06-30 | $1.83M 6-K · filed 2020-09-01 | -$528.08K 6-K · filed 2020-09-01 | |||||
| 2019-03-31 | $0.00 20-F · filed 2021-04-21 | ||||||
| 2018-12-31 | $0.00 20-F · filed 2021-04-21 | $3.24M 20-F · filed 2019-04-23 | |||||
| 2018-06-30 | -$152.56K 6-K · filed 2019-08-29 | $2.79M 6-K · filed 2019-08-29 | |||||
| 2017-12-31 | $2.58M 20-F · filed 2020-03-31 | ||||||
| 2017-06-30 | $7.00M 6-K · filed 2018-09-27 | $2.67M 6-K · filed 2018-09-27 | |||||
| 2016-12-31 | $8.73M 20-F · filed 2019-04-23 | ||||||
| 2016-06-30 | $976.45K 6-K · filed 2017-08-10 | $1.68M 6-K · filed 2017-08-10 | $12.45M derived: sum of 3 quarters · filed 2018-07-18 | $13.09M derived: sum of 4 quarters · filed 2018-07-18 | |||
| 2016-03-31 | $704.34K 10-Q · filed 2016-05-12 | $11.47M derived: sum of 2 quarters · filed 2018-07-18 | $12.11M derived: sum of 3 quarters · filed 2018-07-18 | $12.11M derived: sum of 4 quarters · filed 2018-07-18 | |||
| 2015-12-31 | $10.77M derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | $11.41M derived: sum of 2 quarters · filed 2018-07-18 | $11.41M derived: sum of 3 quarters · filed 2018-07-18 | $11.41M 20-F · filed 2018-07-18 | |||
| 2015-09-30 | $638.69K 10-Q · filed 2015-11-23 | $638.69K derived: sum of 2 quarters · filed 2017-04-14 | $638.69K 10-Q · filed 2015-11-23 | $638.69K derived: sum of 4 quarters · filed 2017-04-14 | |||
| 2015-06-30 | $0.00 6-K · filed 2017-04-14 | $0.00 6-K · filed 2017-04-14 | $0.00 derived: sum of 3 quarters · filed 2017-04-14 | $0.00 derived: sum of 4 quarters · filed 2017-04-14 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-12 | $0.00 derived: sum of 2 quarters · filed 2017-03-31 | $0.00 derived: sum of 3 quarters · filed 2017-03-31 | ||||
| 2014-12-31 | $0.00 derived: 20-F 12 month − 10-Q 9 month · filed 2017-03-31 | $0.00 derived: sum of 2 quarters · filed 2017-03-31 | $0.00 20-F · filed 2017-03-31 | ||||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-23 | $0.00 10-Q · filed 2015-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |